144 related articles for article (PubMed ID: 22111834)
1. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Vine KL; Indira Chandran V; Locke JM; Matesic L; Lee J; Skropeta D; Bremner JB; Ranson M
Curr Cancer Drug Targets; 2012 Jan; 12(1):64-73. PubMed ID: 22111834
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor.
Indira Chandran V; Matesic L; Locke JM; Skropeta D; Ranson M; Vine KL
Cancer Lett; 2012 Mar; 316(2):151-6. PubMed ID: 22115965
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
4.
Belfiore L; Saunders DN; Ranson M; Vine KL
Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32645963
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
Stutchbury TK; Al-Ejeh F; Stillfried GE; Croucher DR; Andrews J; Irving D; Links M; Ranson M
Mol Cancer Ther; 2007 Jan; 6(1):203-12. PubMed ID: 17237280
[TBL] [Abstract][Full Text] [Related]
6. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma.
Jhaveri A; Deshpande P; Pattni B; Torchilin V
J Control Release; 2018 May; 277():89-101. PubMed ID: 29522834
[TBL] [Abstract][Full Text] [Related]
7. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
8. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
[TBL] [Abstract][Full Text] [Related]
9. Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.
Vine KL; Lobov S; Indira Chandran V; Harris NL; Ranson M
Pharm Res; 2015 Mar; 32(3):1045-54. PubMed ID: 25231010
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.
Amreddy N; Muralidharan R; Babu A; Mehta M; Johnson EV; Zhao YD; Munshi A; Ramesh R
Int J Nanomedicine; 2015; 10():6773-88. PubMed ID: 26604751
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.
Zhang Y; Kenny HA; Swindell EP; Mitra AK; Hankins PL; Ahn RW; Gwin K; Mazar AP; O'Halloran TV; Lengyel E
Mol Cancer Ther; 2013 Dec; 12(12):2628-39. PubMed ID: 24061648
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer.
Anabousi S; Bakowsky U; Schneider M; Huwer H; Lehr CM; Ehrhardt C
Eur J Pharm Sci; 2006 Dec; 29(5):367-74. PubMed ID: 16952451
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
14. Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy.
Wu H; Yao L; Mei J; Li F
Int J Clin Exp Pathol; 2015; 8(1):207-16. PubMed ID: 25755707
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex.
Kang T; Jiang M; Jiang D; Feng X; Yao J; Song Q; Chen H; Gao X; Chen J
Mol Pharm; 2015 Aug; 12(8):2947-61. PubMed ID: 26149889
[TBL] [Abstract][Full Text] [Related]
16. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer targeted therapy: Folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin.
Tan S; Wang G
Biomed Pharmacother; 2018 Jun; 102():55-63. PubMed ID: 29549729
[TBL] [Abstract][Full Text] [Related]
18. Transferrin-oligomers as potential carriers in anticancer drug delivery.
Lim CJ; Shen WC
Pharm Res; 2004 Nov; 21(11):1985-92. PubMed ID: 15587919
[TBL] [Abstract][Full Text] [Related]
19. Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
Vine KL; Locke JM; Bremner JB; Pyne SG; Ranson M
Bioorg Med Chem Lett; 2010 May; 20(9):2908-11. PubMed ID: 20363130
[TBL] [Abstract][Full Text] [Related]
20. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
